Adjuvant analgesics in neuropathic pain

European Journal of Anaesthesiology

Volumn 26, Issue 2, 2009, Pages 96-100

  Kong, Vincent K F ^a   Irwin, Michael G ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adjuvants pharmaceutical; Analgesics; Chronic; Pain

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABINOID; CANNABIS; CAPSAICIN; CARBAMAZEPINE; DESIPRAMINE; DULOXETINE; GABAPENTIN; IMIPRAMINE; LIDOCAINE; OMEGA CONOTOXIN MVIIA; PHENYTOIN; PLACEBO; PREGABALIN; TOPICAL AGENT; VENLAFAXINE; ANALGESIC AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ANALGESIA; ASTHENIA; BLURRED VISION; BURNING SENSATION; CONFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HEADACHE; HUMAN; NAUSEA; NEUROPATHIC PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; TRIGEMINUS NEURALGIA; WEIGHT GAIN; XEROSTOMIA; ANIMAL; CHRONIC DISEASE; CRANIAL NEUROPATHY; PAIN;

ADJUVANTS, PHARMACEUTIC; ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CRANIAL NERVE DISEASES; HUMANS; PAIN;

EID: 61549108581     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e328318c706     Document Type: Review

References (30)

1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-289.
2. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med 2003;348:1279.
3. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-1733.
4. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses: sometimes informative, usually misleading. Br Med J 1999;318:1548-1551.
5. Burchiel KJ. Carbamazepine inhibits spontaneous activity in experimental neuromas. Exp Neurol 1988;102:249-253.
6. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 2005: CD005451.
7. Yaari Y, Devor M. Phenytoin suppresses spontaneous ectopic discharge in rat sciatic nerve neuromas. Neurosci Lett 1985;58:117-122.
8. Wiffen P, Collins S, McQuay H, et al. Anticonvulsants drugs for acute and chronic pain. Cochrane Database Syst Rev 2005: CD001133.
9. Maneuf YP, Gonzalez MI, Sutton KS, et al. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003;60:742-750.
10. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005: CD005452.
11. Gilron I, Flatters SJ. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manage 2006;11:16A-29A.
12. Dworkin RH, Thakur R, Griesing T, et al. Randomized clinical trials of pregabalin for neuropathic pain: methods, results, and implications. Prog Neurother Neuropsychopharmacol 2008;3:167-187.
13. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
14. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 2007;64:1475-1482.
15. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409.
16. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007: CD005454.
17. Siepmann T, Mueck-Weymann M, Oertel R, et al. The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. Pharmacopsychiatry 2008;41:146-150.
18. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007; 29 (Suppl) : 2536-2546.
19. Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med 2007;8:397-409.
20. Armstrong DG, Chappell AS, Le TK, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Med 2007;8:410-418.
21. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44.
22. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-158.
23. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev 2007;87:165-217.
24. Veronesi B, Oortgiesen M. The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci 2006;89:1-3.
25. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. Br Med J 2004;328:991-994. (Pubitemid 38530371)
26. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180.
27. Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007;23:17-24.
28. Skov MJ, Beck JC, de Kater AW, Shopp GM. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol 2007;26:411-421.
29. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-294.
30. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 2007;12:113-126.